Aktis Oncology, Inc.
AKTS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002035832
In the last 90 days, Aktis Oncology, Inc. insiders filed 0 open-market purchases and 5 sales; 113 institutions reported holding it in 13F filings for Q2 2026, worth $1.10B in total; Soros Fund Management is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $3.23M in total
- 5
- 13F holdersQ2 2026, +46 vs. previous quarter
- 113
- 13F valueReported value at the end of Q2 2026
- $1.10B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding AKTS, Q2 2026
1 superinvestor reports holding Aktis Oncology, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
<0.1%
Aktis Oncology, Inc.'s share of the portfolio
- Shares
- 100,000
- Value
- $3.22M
Latest insider trades
Open-market purchases and sales by Aktis Oncology, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)4:05 PM ET | Sep 23 | 1 day | Czibere AkosChief Medical Officer | SSale | −12.5K | $20.69 | −$258.6K | −100.0%0 after | 2 lots10b5-1 |
| Jul 21, 2026 (view filing)8:50 PM ET | Jul 20 | 1 day | Herrmann KenDirector | SSale | −4.86K | $24.56 | −$119.3K | −100.0%0 after | 2 lots |
| Jul 20, 2026 (view filing)5:34 PM ET | Jul 17 | 3 days | Herrmann KenDirector | SSale | −3.06K | $25.21 | −$77.3K | −100.0%0 after | |
| Jul 10, 2026 (view filing)6:11 AM ET | Jul 8 | 2 days | Ron-Bigger ShulamitChief Operating Officer | SSale | −50.0K | $27.75 | −$1.39M | −100.0%0 after | 3 lots |
| Jul 10, 2026 (view filing)6:10 AM ET | Jul 8 | 2 days | Czibere AkosChief Medical Officer | SSale | −50.0K | $27.77 | −$1.39M | −100.0%0 after | 3 lots |
| Jan 14, 2026 (view filing)6:19 PM ET | Jan 12 | 2 days | Evnin Luke and 7 others10% Owner | PPurchase | +1.11M | $18.00 | +$20.0M | +12.2%10.3M after | Duplicate filing |
| Jan 14, 2026 (view filing)6:17 PM ET | Jan 12 | 2 days | Gadicke Ansbert and 2 others10% Owner | PPurchase | +1.11M | $18.00 | +$20.0M | +12.2%10.3M after | |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Foley ToddDirector, 10% Owner | PPurchase | +232.9K | $18.00 | +$4.19M | +5.8%4.24M after | |
| Jan 12, 2026 (view filing)8:28 PM ET | Jan 12 | Same day | Nodelman Oleg and 1 otherDirector | PPurchase | +2.22M | $18.00 | +$40.0M | New position347.3K after | 2 lots |
| Jan 12, 2026 (view filing)5:10 PM ET | Jan 12 | Same day | Vida Ventures II, LLC and 1 other10% Owner | PPurchase | +835.0K | $18.00 | +$15.0M | New position157.4K after | 2 lotsDuplicate filing |
Top 10 13F holders, Q2 2026
The largest institutional positions in Aktis Oncology, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MPM Oncology Impact Management LP | 4,835,872 | $155.9M | 9.50% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 4,824,469 | $155.5M | 7.71% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 3,070,219 | $99.0M | 15.04% | −91,129−2.9% | Reduced |
| BlackRock, Inc. | 2,278,358 | $73.4M | 0.00% | +166,231+7.9% | Added |
| T. Rowe Price Investment Management, Inc. | 2,051,447 | $66.1M | 0.04% | −72,365−3.4% | Reduced |
| Wellington Management Group LLP | 1,966,244 | $63.4M | 0.01% | −350,800−15.1% | Reduced |
| RTW Investments, LP | 1,592,043 | $51.3M | 0.44% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 1,314,405 | $42.4M | 0.37% | −188,679−12.6% | Reduced |
| Jupiter Topco LLC | 1,314,267 | $42.4M | 0.02% | +1,314,267 | New |
| Baker Bros. Advisors LP | 996,351 | $32.1M | 0.16% | 00.0% | Unchanged |